Patents by Inventor Martin Alexander Lowe

Martin Alexander Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antimalarial hexahydropyrimidine analogues
    Patent number: 11479546
    Abstract: The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: October 25, 2022
    Inventors: Teresa De Haro Garcia, Lloyd Malcolm King, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES
    Publication number: 20220289685
    Abstract: A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Application
    Filed: August 17, 2020
    Publication date: September 15, 2022
    Inventors: Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm MacCoss, Richard David Taylor, Zhaoning Zhu, Rose Elizabeth Chappell
  • Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors
    Patent number: 11136310
    Abstract: A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: October 5, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Rebecca Louise Charlton, Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Trevor Morgan, Richard David Taylor, Zhaoning Zhu
  • Antimalarial Hexahydropyrimidine Analogues
    Publication number: 20210094941
    Abstract: The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria.
    Type: Application
    Filed: April 2, 2019
    Publication date: April 1, 2021
    Inventors: Teresa De Haro Garcia, Lloyd Malcolm King, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
    Publication number: 20200399268
    Abstract: The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.
    Type: Application
    Filed: February 15, 2019
    Publication date: December 24, 2020
    Inventors: Jag Paul Heer, Michal Sarah Hallside, Adam Peter Smalley, Josep Llaveria Cros, Benedicte Lallemand, Martin Alexander Lowe, Xianfu Li, Anthony John Richardson, Robert James Townsend
  • IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS
    Publication number: 20200283416
    Abstract: A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Application
    Filed: November 24, 2016
    Publication date: September 10, 2020
    Inventors: Rebecca Louise Charlton, Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Trevor Morgan, Richard David Taylor, Zhaoning Zhu
  • Fused pentacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10654861
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 19, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Jean Keyaerts, Luce Elsa Lepissier, Martin Alexander Lowe
  • Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors
    Patent number: 10464932
    Abstract: A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: November 5, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity
    Patent number: 10287299
    Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: May 14, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity
    Publication number: 20190100525
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 4, 2019
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Jean Keyaerts, Luce Elsa Lepissier, Martin Alexander Lowe
  • Iminothiadiazinane Dioxide Derivatives as Plasmepsin V Inhibitors
    Publication number: 20190040053
    Abstract: A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Application
    Filed: February 22, 2017
    Publication date: February 7, 2019
    Inventors: Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • Purine derivatives as modulators of TNF activity
    Patent number: 9988383
    Abstract: A series of substituted purine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 5, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity
    Publication number: 20180134728
    Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: June 7, 2016
    Publication date: May 17, 2018
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • Tetrahydroimidazopyridine derivatives as modulators of TNF activity
    Patent number: 9932334
    Abstract: A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Tetrahydroimidazopyridine derivatives as modulators of TNF activity
    Patent number: 9834553
    Abstract: A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: December 5, 2017
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity
    Publication number: 20170129883
    Abstract: A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: May 11, 2017
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • TNF -? modulating benzimidazoles
    Patent number: 9550737
    Abstract: A series of benzimidazole derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: January 24, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Daniel Christopher Brookings, Mark Daniel Calmiano, Ellen Olivia Gallimore, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Boris Kroeplien, Fabien Claude Lecomte, Martin Alexander Lowe, Timothy John Norman, John Robert Porter, Joanna Rachel Quincey, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu, Anne Marie Foley
  • Tetrahydroimidazopyridine Derivatives As Modulators of TNF Activity
    Publication number: 20160304514
    Abstract: A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Purine Derivatives As Modulators of TNF Activity
    Publication number: 20160297818
    Abstract: A series of substituted purine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 13, 2016
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Imidazopyridine derivatives as modulators of TNF activity
    Patent number: 9309243
    Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: April 12, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Praful Tulshi Chovatia, Anne Marie Foley, Ellen Olivia Gallimore, Laura Jane Gleave, Alexander Heifetz, Helen Tracey Horsley, Martin Clive Hutchings, Victoria Elizabeth Jackson, James Andrew Johnson, Craig Johnstone, Boris Kroeplien, Fabien Claude Lecomte, Deborah Leigh, Martin Alexander Lowe, James Madden, John Robert Porter, Joanna Rachel Quincey, Laura Claire Reed, James Thomas Reuberson, Anthony John Richardson, Sarah Emily Richardson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu